Mediclinic Intnl plc - Holding(s) in Company

05/08/2022

PDF Version
RNS Number : 0919V
Mediclinic International plc
05 August 2022
 

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

South African income tax number: 9432434182

('Mediclinic', the 'Company', or the 'Group')

 

5 August 2022

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B8HX8Z88

Issuer Name

MEDICLINIC INTERNATIONAL PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

JPMorgan Chase & Co.

City of registered office (if applicable)

 

Country of registered office (if applicable)

US

4. Details of the shareholder

Name

City of registered office

Country of registered office

J.P. Morgan Securities plc



5. Date on which the threshold was crossed or reached

02-Aug-2022

6. Date on which Issuer notified

04-Aug-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

1.081097

7.024640

8.105737

59759040

Position of previous notification (if applicable)

0.951405

6.162299

7.113704


8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00B8HX8Z88


7970320


1.081097

Sub Total 8.A

7970320

1.081097%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 





Sub Total 8.B1




8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Cash-settled Equity Swap

23/11/2022

23/11/2022

Cash

26868653

3.644473

Cash-settled Equity Swap

04/01/2023

04/01/2023

Cash

131854

0.017885

Cash-settled Equity Swap

01/02/2023

01/02/2023

Cash

16152

0.002191

Cash-settled Equity Swap

22/02/2023

22/02/2023

Cash

32718

0.004438

Cash-settled Equity Swap

17/03/2023

17/03/2023

Cash

38171

0.005178

Cash-settled Equity Swap

30/05/2023

30/05/2023

Cash

99

0.000013

Cash-settled Equity Swap

02/06/2023

02/06/2023

Cash

17599790

2.387241

Cash-settled Equity Swap

04/07/2023

04/07/2023

Cash

6773196

0.918719

Cash-settled Equity Swap

12/07/2023

12/07/2023

Cash

12874

0.001746

Cash-settled Equity Swap

09/08/2023

09/08/2023

Cash

759

0.000103

Cash-settled Equity Swap

16/08/2023

16/08/2023

Cash

900

0.000122

Cash-settled Equity Swap

21/08/2023

21/08/2023

Cash

584

0.000079

Cash-settled Equity Swap

22/08/2023

22/08/2023

Cash

598

0.000081

Cash-settled Equity Swap

03/10/2023

03/10/2023

Cash

5565

0.000755

Cash-settled Equity Swap

05/01/2027

05/01/2027

Cash

240590

0.032634

Cash-settled Equity Swap

06/07/2027

06/07/2027

Cash

647

0.000088

Cash-settled Equity Swap

03/08/2027

03/08/2027

Cash

289

0.000039

Cash-settled Equity Swap

09/07/2029

09/07/2029

Cash

65281

0.008855

Sub Total 8.B2


51788720

7.024640%

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

JPMorgan Chase & Co.

J.P. Morgan Securities plc


7.024640

7.024640%

JPMorgan Chase & Co.

JPMorgan Chase Bank, National Association




JPMorgan Chase & Co.

J.P. Morgan Equities South Africa Proprietary Limited




JPMorgan Chase & Co.

J.P. Morgan SE




10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Chain of controlled undertakings:

JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Securities plc (100%)

JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)

JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Equities South Africa Proprietary Limited (100%)

JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan SE (100%)

12. Date of Completion

04-Aug-2022

13. Place Of Completion

London

 

About Mediclinic International plc

 

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

 

The Group's core purpose is to enhance the quality of life.

 

Its vision is to be the partner of choice that people trust for all their healthcare needs.

 

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

 

At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 20 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

 

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

 

Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

 

 

For further information, please contact:

 

Company Secretary, Link Company Matters Limited

Caroline Emmet

+44 (0)333 300 1930

 

Investor Relations

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

 

Media queries

FTI Consulting

Ben Atwell/Ciara Martin - United Kingdom

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

 

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUVVWRUAUWRRR

Website Notice Block